Y-Intercept (HK)’s Clearside Biomedical CLSD Stock Holding History

Y-Intercept (HK)’s Portfolio CLSD Stock Details CLSD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-2,275	Closed	-$52.2K	–	1461
2024 Q1	$52.2K	Buy	+2,275	New	+$49K	﹤0.01%	1303

Other funds holding CLSD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Y-Intercept (HK)'s CLSD Position: Q2 2024 in Review

Y-Intercept (HK) sold out of Clearside Biomedical (CLSD) in Q2 2024, closing a stake of 2,275 shares — an estimated $52.2K sold.

Y-Intercept (HK) first reported a position in CLSD in Q1 2024 and held it in 1 quarter. The position peaked at $52.2K in Q1 2024. 47 funds tracked by Wall St. Rank hold CLSD as of Q2 2024.

Y-Intercept (HK) reported no remaining Clearside Biomedical position as of Q2 2024 after selling out during the quarter.
Y-Intercept (HK) sold 2,275 Clearside Biomedical shares in Q2 2024, an estimated $52.2K.
Y-Intercept (HK) first reported a position in Clearside Biomedical in Q1 2024 and held it in 1 quarter.
Y-Intercept (HK)'s Clearside Biomedical position peaked at $52.2K in Q1 2024.
47 funds tracked by Wall St. Rank held Clearside Biomedical as of Q2 2024.

Based on Y-Intercept (HK)'s 13F filing for Q2 2024, filed 14 Aug 2024.